• VistaGen disclosed positive exploratory findings for fasedienol nasal spray in very severe social anxiety disorder at Psych Congress 2026.
• Analyses signaled symptom improvement versus placebo during a public speaking challenge, despite a broader Phase 3 study missing its main goal.
• Repeat dosing suggested added benefit, supporting further evaluation of the program’s dosing approach.
• Safety and tolerability remained consistent with prior trials, with no serious drug-related safety signals identified.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. VistaGen Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240700PRIMZONEFULLFEED9833013) on September 24, 2026, and is solely responsible for the information contained therein.